Page 13 - AN-3-1

Advanced Neurology PSD-95 in neurodevelopmental disorders

Table 2. Selected examples of changes in PSD‑95 levels affected by neurodevelopmental pharmacotherapies in cells and
rodent studies
Medications Author Model Disease model Treatment Results Conclusion
Antipsychotics Takaki Neuron Schizophrenia (i) Haloperidol (i) Aripiprazole Choosing the proper
et al. 69 culture (1 or 10 µM) (1 mM or 10 mM) and antipsychotic medication and
(ii) Clozapine clozapine determining the correct dosage
(1 or 10 µM) (1 mM): Increase in may be crucial in safeguarding
(iii) Aripiprazole PSD-95, the number of dendritic spines in individuals
(1 or 10 µM) spines, phosphorylated Akt with schizophrenia.
(iv) GSK-3 inhibitor Thr308 and Ser473, and
(1, 5, or 10 µM) phosphorylated
GSK-3 beta Ser9
(ii) Haloperidol (1 mM or
10 mM) or clozapine
(10 mM): Decrease in
PSD-95, the number of
spines, phosphorylated Akt
Thr308 and Ser473, and
phosphorylated
GSK-3 beta Ser9
(iii) GSK inhibitor: Increase in
PSD-95
Park Neuron Toxic conditions (i) Olanzapine (10, 50, (i) Olanzapine, quetiapine and The increased expression
et al. 68 culture induced by B27 and 100 µM), aripiprazole: Increase in of synaptic proteins and
deprivation (ii) Quetiapine PSD-95 and BDNF the expansion of dendritic
(0.1, 1, and (ii) Ziprasidone: Did not affect structures could be essential
10 µM) PSD-95 or BDNF consequences of certain
(iii) Aripiprazole (iii) Haloperidol: Decrease in atypical antipsychotic
(0.1, 1, and the levels of PSD-95. medications. However,
10 µM) (iv) All drugs increased the haloperidol may exhibit unique
(iv) Ziprasidone outgrowth of hippocampal effects or actions in this regard.
(0.1, 1, and dendrites through PI3K
10 µM), signaling, whereas
(v) Haloperidol haloperidol had no effect.
(0.1, 1, and 10 µM)
Iasevoli SD rats NA (i) Haloperidol (i) Haloperidol and The rise in PSD-95 levels
et al. 76 (0.8 mg/kg) Ziprasidone: Increase in following extended
(ii) Ziprasidone PSD-95 expression at the antipsychotic treatment
(4 mg/kg) early time-point in the might be seen as an indirect
(iii) Clozapine ACC, MAC, and MC. mechanism that plays a role in
(15 mg/kg) (ii) Clozapine: Upregulated reversing hyperdopaminergic
Homer1a expression in the activity in schizophrenia.
nucleus accumbens.
Selective Aguiar BCCAO Brain ischemia Escitalopram Restored BDNF, SYN, and Escitalopram reduced the
serotonin et al. 90 rat model (20 mg/kg) PSD-95 protein levels in the decline in PSD-95 protein levels
reuptake hippocampus. caused by BCCAO.
inhibitors Seo Neuron Depression (B27) (i) Fluoxetine (i) Fluoxetine, paroxetine, Some antidepressant
(SSRIs) et al. 93 Culture (0.1, 1, and 10 µM) sertraline: Increase in medications can boost the
(ii) Paroxetine BDNF levels of synaptic proteins
(0.1, 1, and 10 µM) (ii) All drugs+B27 prevented and promote the growth of
(iii) Sertraline e the decrease of PSD-95, dendrites in hippocampal
(0.05, 0.1, and BDNF and synaptophysin: neurons.
1 µM) Increase in dendritic
(iv) Tranylcypromine outgrowth in hippocampal
(1, 10, and 50 µM) cells
(v) Tianeptine (10, 50,
and 100 µM)
(vi) Escitalopram
(1, 10, and 50 µM)
(Cont’d...)

Volume 3 Issue 1 (2024) 7 https://doi.org/10.36922/an.2095